XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition

The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended September 30, 2022 (in thousands):

Opening balance, December 31, 2021			$	32,333
Payments received in advance			11,319
Revenue from performance obligations satisfied during reporting period			(4,005)
Closing balance, September 30, 2022			$	39,647
Current portion of deferred revenue			$	15,249
Long-term portion of deferred revenue			24,398
Total deferred revenue, September 30, 2022			$	39,647

The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):

			Three Months Ended September 30, 2022																		Nine Months Ended September 30, 2022
			Mundipharma						Janssen						Melinta						Mundipharma						Janssen						Melinta
Revenue from Collaboration and License Agreements:
Point in Time:
License of Intellectual Property			$	3,252					$	—					$	25,885					$	3,252					$	816					$	25,885
Clinical Drug Supply			459						—						—						459						—						—
Over Time:
Research and Development Services			3,945						6,250						328						7,965						11,235						328
Clinical Supply Services			363						262						—						792						3,337						—
Total Revenue from Collaboration and License Agreements			$	8,019					$	6,512					$	26,213					$	12,468					$	15,388					$	26,213

			Three Months Ended September 30, 2021																		Nine Months Ended September 30, 2021
			Mundipharma						Janssen						Melinta						Mundipharma						Janssen						Melinta
Revenue from Collaboration and License Agreements:
Point in Time:
License of Intellectual Property			$	—					$	—					$	—					$	—					$	27,000					$	—
Clinical Drug Supply			—						—						—						—						—						—
Over Time:
Research and Development Services			3,033						2,072						—						7,795						3,747						—
Clinical Supply Services			237						1,734						—						598						3,207						—
Total Revenue from Collaboration and License Agreements			$	3,270					$	3,806					$	—					$	8,393					$	33,954					$	—

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration